AGF Investments America Inc. reduced its position in shares of Medtronic PLC (NYSE:MDT) by 8.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 113,138 shares of the medical technology company’s stock after selling 10,095 shares during the quarter. Medtronic makes up about 3.7% of AGF Investments America Inc.’s holdings, making the stock its 7th biggest holding. AGF Investments America Inc.’s holdings in Medtronic were worth $10,305,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Cordasco Financial Network purchased a new stake in shares of Medtronic in the 1st quarter worth about $27,000. Pin Oak Investment Advisors Inc. grew its position in shares of Medtronic by 158.0% in the 4th quarter. Pin Oak Investment Advisors Inc. now owns 369 shares of the medical technology company’s stock worth $34,000 after buying an additional 226 shares during the period. Spectrum Management Group Inc. grew its position in shares of Medtronic by 353.8% in the 1st quarter. Spectrum Management Group Inc. now owns 413 shares of the medical technology company’s stock worth $38,000 after buying an additional 322 shares during the period. Mackey Komara & Dankovich LLC purchased a new stake in shares of Medtronic in the 1st quarter worth about $38,000. Finally, Capital Financial Planning LLC purchased a new stake in shares of Medtronic in the 4th quarter worth about $42,000. Institutional investors own 80.10% of the company’s stock.
In other Medtronic news, EVP Geoffrey Martha sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $96.05, for a total transaction of $1,056,550.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard H. Anderson bought 10,900 shares of the firm’s stock in a transaction on Friday, May 24th. The shares were purchased at an average price of $92.40 per share, for a total transaction of $1,007,160.00. Following the purchase, the director now owns 89,912 shares in the company, valued at approximately $8,307,868.80. The disclosure for this purchase can be found here. 0.28% of the stock is currently owned by company insiders.
Several analysts recently commented on the stock. Oppenheimer set a $104.00 price objective on shares of Medtronic and gave the company a “buy” rating in a research report on Wednesday, February 20th. Wells Fargo & Co cut their price objective on shares of Medtronic from $101.00 to $100.00 and set a “market perform” rating on the stock in a research report on Thursday, April 4th. Citigroup increased their price objective on shares of Medtronic from $95.00 to $101.00 and gave the company a “neutral” rating in a research report on Monday, February 25th. Barclays reissued a “buy” rating and set a $104.00 price objective on shares of Medtronic in a research report on Wednesday, February 20th. Finally, Northland Securities reissued a “hold” rating and set a $84.00 price objective on shares of Medtronic in a research report on Monday, March 18th. Eight analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $103.95.
Shares of NYSE:MDT opened at $97.53 on Thursday. Medtronic PLC has a twelve month low of $81.66 and a twelve month high of $100.15. The company has a current ratio of 2.59, a quick ratio of 2.15 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $130.24 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.50 and a beta of 0.68.
Medtronic (NYSE:MDT) last issued its quarterly earnings data on Thursday, May 23rd. The medical technology company reported $1.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.47 by $0.07. Medtronic had a net margin of 15.15% and a return on equity of 14.16%. The firm had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.12 billion. During the same quarter in the prior year, the business earned $1.42 EPS. The business’s quarterly revenue was up .0% on a year-over-year basis. As a group, analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2019/06/13/agf-investments-america-inc-lowers-position-in-medtronic-plc-nysemdt.html.
Medtronic Company Profile
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
See Also: What is a portfolio manager?
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.